Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men

References

• Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46: 1032–7
   Google Scholar
• Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Anti-microb Agents Chemother 2002;46:1581–2
   PubMed Web of Science ®Google Scholar
• Manavathu EK, Cutright JL, Loebenberg D, et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000;46: 229–34
   Google Scholar
• Sabatelli FJ, Loebenberg D, Mendrick CA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against approximately 18 000 strains of clinically significant yeasts and moulds. Poster presented at: 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30–November 2, 2004; Washington, DC
   Google Scholar
• Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000;44:780–2
   PubMed Web of Science ®Google Scholar
• Lozano-Chiu M, Arikan S, Paetznick VL, et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999;43: 589–91
   Google Scholar
• Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002;46: 2310–2
   PubMed Web of Science ®Google Scholar
• Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). Poster presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30–November 2, 2004; Washington, DC
   Google Scholar
• Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658–66
   PubMed Web of Science ®Google Scholar
• van Burik JH, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis [serial online] 2006;42 [last accessed 11 January 2006]
   Google Scholar
• Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788–95
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition December 3–7, 2006 Anaheim, CA, 2006
   Google Scholar
• Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218–22
   Web of Science ®Google Scholar
• Gubbins PO, Amsden JR. Drug–drug interactions of antifungal agents and implications for patient care. Exp Opin Pharmacother 2005;6:2231–43
   PubMed Web of Science ®Google Scholar
• Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543–51
   PubMed Web of Science ®Google Scholar
• Krieter PA, Achanfuo-Yeboah J, Shea M, et al. Biliary excretion and enterohepatic circulation of the antifungal agent 14C-SCH 56592 in male and female rats [abstract]. Proceedings of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26–29, 1999:34 [abstract 1199]
   Google Scholar
• Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645–53
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Morb Mortal Wkly Rep 2000;49:185–9
   PubMedGoogle Scholar
• Maslo C, Bure-Rossier A, Girard PM, et al. Clinical and bacteriologic impact of rifabutin prophylaxis for Mycobacterium avium complex infection in patients with human immunodeficiency virus infection. Clin Infect Dis 1997;24:344–9
   PubMed Web of Science ®Google Scholar
• Wright J. Current strategies for the prevention and treatment of disseminated Mycobacterium avium complex infection in patients with AIDS. Pharmacotherapy 1998;18:738–47
   PubMed Web of Science ®Google Scholar
• Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996;22(Suppl 1):S15–S21
   PubMedGoogle Scholar
• Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327–41
   PubMedGoogle Scholar
• Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York (NY): Marcel Dekker; 1982
   Google Scholar
• Benedetti MS, Efthymiopoulos C, Sassella D, et al. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990;20:1113–9
   PubMed Web of Science ®Google Scholar
• Oesch F, Arand M, Benedetti MS, et al. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 1996;37:1111–9
   PubMed Web of Science ®Google Scholar
• Reinach B, de Sousa G, Dostert P, et al. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999;121:37–48
   PubMed Web of Science ®Google Scholar
• Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267–71
   PubMed Web of Science ®Google Scholar
• Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985–92
   PubMed Web of Science ®Google Scholar
• Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165–74
   PubMed Web of Science ®Google Scholar
• Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12(Suppl 3):S327–S333
   PubMedGoogle Scholar
• Ghahramani P, Purkins L, Kleinermans D, et al. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole [abstract]. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17–20, 2000 Toronto, Ontario, Canada 2000 [abstract 844]
   Google Scholar
• VFEND® (voriconazole) for injection, VFEND® (voriconazole) tablets, VFEND® (voriconazole) for oral suspension [prescribing information]. New York, NY: Pfizer Inc; February 2005
   Google Scholar
• Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998;18:83–97
   PubMed Web of Science ®Google Scholar
• Kuper JI, D’Aprile M. Drug–drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000;39:203–14
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Narang PK, Li R, et al. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573–6
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown BA, Girard WM, et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594–8
   PubMed Web of Science ®Google Scholar
• Narang PK, Trapnell CB, Schoenfelder JR, et al. Fluconazole and enhanced effect of rifabutin prophylaxis. New Engl J Med 1994;330:1316–7
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol 1998;42:557–70
   PubMed Web of Science ®Google Scholar
• Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Ann Pharmacother 1995;29:1149–55
   PubMed Web of Science ®Google Scholar